News

Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed

Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first

The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers,

GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the

The mid-stage trial met the primary endpoint by recording a statistically significant improvement from baseline in motor symptoms in patients treated with tavapadon in comparison with those in

The opinion was based on positive findings from the Phase III JAVELIN Renal 101 study, which demonstrated a significant extension in median progression-free survival (PFS) and a clinically

“There is a pressing need for effective treatments for patients suffering from the profound defects associated with FAOD, and we believe REN001 represents a promising new therapy. Orphan

The FDA has approved new drug applications (sNDAs) for Pifeltro in combination with other antiretroviral agents and Delstrigo as a complete regimen for adult patients with HIV-1 infection

The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be